|Chemical and physical data|
|3D model (JSmol)|
|(what is this?)|
BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2 inverse agonist. BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity. The activity produced by this compound is disputed, with some sources referring to it as a CB2 agonist rather than an inverse agonist; this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.
- New, DC; Wong, YH (2003). “BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates”. FEBS Letters. 536 (1–3): 157–60. doi:10.1016/S0014-5793(03)00048-6. PMID 12586356.
- Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). “Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor”. British Journal of Pharmacology. 139 (4): 775–86. doi:10.1038/sj.bjp.0705304. PMC 1573900. PMID 12813001.
- Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). “Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation”. Endocrinology. 141 (1): 118–26. doi:10.1210/en.141.1.118. PMID 10614630.
- Scutt, A; Williamson, EM (2007). “Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors”. Calcified tissue international. 80 (1): 50–9. doi:10.1007/s00223-006-0171-7. PMID 17205329.